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The high rate of metastasis and recurrence among
melanoma patients indicates the existence of cells
within melanoma that have the ability to both initiate
metastatic programs and bypass immune recog-
nition. Here, we identify CD47 as a regulator of
melanoma tumor metastasis and immune evasion.
Protein and gene expression analysis of clinical mel-
anoma samples reveals that CD47, an anti-phago-
cytic signal, correlates with melanoma metastasis.
Antibody-mediated blockade of CD47 coupled with
targeting of CD271+ melanoma cells strongly inhibits
tumor metastasis in patient-derived xenografts. This
therapeutic effect is mediated by drastic changes
in the tumor and metastatic site immune micro-
environments, both of whichwhich exhibit greatly
increased density of differentiated macrophages
and significantly fewer inflammatory monocytes,
pro-metastatic macrophages (CCR2+/VEGFR1+),
and neutrophils, all of which are associated with dis-
ease progression. Thus, antibody therapy that acti-
vates the innate immune response in combination
with selective targeting of CD271+ melanoma cells
represents a powerful therapeutic approach against
metastatic melanoma.INTRODUCTION
Melanoma, the most lethal type of skin cancer, has high meta-
static potential andarises ascells ofmelanocytic lineage undergo
tumorigenic transformation. Although surgical removal and treat-
ment of primary tumors prior to metastasis have a favorable
5-year survival rate for 90% of patients, this figure drops sharply
to 65% for those diagnosedwith regional metastatic disease and
to 15% for those diagnosed with distant metastases (AmericanCell
This is an open access article under the CC BY-NCancer Society, 2015). Despite being one of the most immuno-
genic tumors, the success rate of immune-therapeutic regimens
in achieving long-term, complete responses in metastatic mela-
noma patients remains low (Zikich et al., 2013). This might be
due to the fact that the antigens selected for these approaches
do not cover the full spectrum of melanoma cells present in a tu-
mor, including the most dangerous, melanoma-initiating subset,
defined by cluster of differentiation (CD)271 expression (Boiko
et al., 2010; Civenni et al., 2011). In addition, interaction between
tumor cells and the immune microenvironment has been shown
to play a pivotal role in disease progression as well as the ability
of the disease to regress in the presence of activated immune
components (Biswas and Mantovani, 2010; Murdoch et al.,
2008). Importantly, primary melanoma cells that fail to be de-
tected and removed by the innate immune system—macro-
phages in particular—are highly likely to metastasize to visceral
organs and tissues, resulting in incurable disease.
Macrophages comprise a major component of the innate
immune system and act as professional phagocytic cells
throughout the body. Most adult tissue-resident macrophages
differentiate from bone marrow-derived monocytes, with an
exception of microglia and subsets of epidermal Langerhans
cells, which are derived from the yolk sac and fetal liver, respec-
tively (Hoeffel et al., 2012; Sheng et al., 2015). When a tissue un-
dergoes remodeling due to injury or inflammation (also hallmarks
of tumor growth), Ly6Chi/C-C chemokine receptor (CCR)2+
monocytes are rapidly recruited to these sites, where they
extravasate and differentiate into macrophages and certain
types of dendritic cells (Ginhoux and Jung, 2014; Serbina and
Pamer, 2006). In cancer patients, macrophages elicit their activ-
ity by binding to and phagocytosing malignant cells, contributing
to reduced tumor growth (Biswas and Mantovani, 2010). More-
over, macrophages are often found at high concentrations in
the afferent sinuses of lymph nodes and the surrounding blood
vessels, indicating that they constitute a major barrier to the for-
mation of metastases. Conversely, besides their anti-cancer
function, macrophages found at tumor sites can also play a
pro-tumorigenic/metastatic role upon adopting a polarized
phenotype, characterized by the expression of CCR2 andReports 16, 1701–1716, August 9, 2016 ª 2016 The Authors. 1701
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
vascular endothelial growth factor receptor 1 (VEGFR1) (Qian
et al., 2011; Ren et al., 2012). The presence of CCR2+/VEGFR1+
macrophages at metastatic organs creates a favorable microen-
vironment for arriving circulating tumor cells and could augment
tumor colonization (Qian et al., 2011). Precise functional delinea-
tion of macrophages has been hampered by their high degree of
heterogeneity and plasticity that underlies the broad spectrum of
macrophage involvement in very diverse processes such as de-
fense against pathogenic cells, maintenance of tissue integrity,
and immunomodulation. Expression of genes that include
Mrc1 (CD206), Fizz1, Ym1, Mgl1 (CD301a), Arg1, Nos2, and
Il10 has commonly been used to classify macrophage popula-
tions into the M1 and M2 (M2a–M2c) subgroups (Qian and
Pollard, 2010; Roszer, 2015). However, in vivo classification of
macrophages into distinct M1/M2 subtypes based on estab-
lished patterns of gene expression needs to be approached
with caution, and depends in each case on the homeostatic
and pathological conditions of the living tissue from which the
macrophages are being sampled (Franklin et al., 2014; Martinez
and Gordon, 2014). In addition to macrophages, the microenvi-
ronment of the metastatic site can also be affected by the pres-
ence of neutrophils, which are known to respond to inflammation
associated with cancer cell growth (Cools-Lartigue et al., 2013;
Fridlender and Albelda, 2012). Clinical studies indicate that
elevated frequencies of neutrophils at metastatic sites indicate
an adverse prognosis for patients with gastric and lung cancers
(Sarraf et al., 2009; Walsh et al., 2005). Based on these findings,
we hypothesized that a therapeutic approach that activates the
pro-phagocytic response and shifts the balance between anti-
and pro-tumorigenic macrophages and neutrophils would deter-
mine the eventual outcome of progressing metastatic disease.
Tumors of hematopoietic and epithelial origin have recently
been found to avoid macrophage phagocytosis by overexpress-
ing CD47, which is known as a ‘‘don’t eat me’’ signal (Jaiswal
et al., 2009; Mawby et al., 1994; Willingham et al., 2012). CD47
is a transmembrane integrin-associated protein whose ligands
include thrombospondin 1 (TSP1) and signal-regulatory protein
alpha (SIRPa). Cells expressingCD47 interact withmacrophages
via SIRPa (Mawby et al., 1994; Vernon-Wilson et al., 2000); CD47
binding to the macrophage SIRPa receptor leads to the tyrosine
phosphorylation of its cytoplasmic tail and subsequent activation
of Src homology-2 (SH2)-domain-containing protein tyrosine
phosphatases SHP1 andSHP2. Activity of these enzymes results
in cytoplasmic membrane modifications that inhibit macro-
phage-mediated phagocytosis of target cells (Chao et al., 2012;
Okazawa et al., 2005; Vernon-Wilson et al., 2000). Recent studies
found that masking CD47 with anti-CD47monoclonal antibodies
on the surface of hematopoietic and epithelial cancer cells leads
to stimulation of phagocytosis in vitro and decreased tumor
burden in vivo (Jaiswal et al., 2009;Majeti et al., 2009;Willingham
et al., 2012). In addition to SIRPa, CD47 has also been shown to
interact with TSP1 (Isenberg et al., 2006). Disruption of this
signaling network leads to increased radioprotection of normal
tissue cells anddelays tumor growth, including that ofmelanoma,
in syngeneic mouse models of cancer (Maxhimer et al., 2009).
On the other hand, researchers have shown that ligation of
CD47 on the cell surface of breast cancer cell lines or promyelo-
cytic leukemia cells by solubleTSP1 induced their direct killing via1702 Cell Reports 16, 1701–1716, August 9, 2016caspase-independent apoptosis (Johansson et al., 2004; Manna
and Frazier, 2004; Mateo et al., 1999; Saumet et al., 2005). These
seemingly opposite effects of CD47-TSP1 interaction on tumor
fate are likely due to the differences in cancer cell types as well
as systemic tissue levels of TSP1 in vivo.
Our group and others previously demonstrated that melanoma
cells expressing the neural crest stem cell marker CD271 are
capable of initiating tumor growth in vivo and, importantly, also
give rise to melanoma cells capable of metastasis (Boiko et al.,
2010; Civenni et al., 2011; Redmer et al., 2014). CD271 is a
low-affinity nerve growth factor receptor (NGFR/p75) whose
main ligands are neurotrophins, a family of protein growth factors
that stimulate survival and migration of neuronal and neural
crest-derived cell lineages (Marchetti et al., 1993). Subsequently,
overexpression of CD271 was found to positively regulate the
invasive properties of melanoma, enhancing its metastatic po-
tential (Guo et al., 2014; Marchetti et al., 2004). Our experiments
established that upon transplantation into the skin of NOD-scid
IL2Rgammanull mice (NSG) mice, CD271+ melanoma cells iso-
lated from clinical samples can give rise to metastatic tumors
that spread to the lymph nodes, lungs, liver, and kidneys,
mimicking human disease (Boiko et al., 2010). Evasion of im-
mune surveillance during primary tumor growth, dissemination,
and homing to visceral tissues is a main prerequisite for metas-
tasis. Thus, we hypothesized that melanoma tumor cells, espe-
cially metastatic subsets, rely on CD47 expression for phagocy-
tosis blockade and successful colonization of distant organs.We
further thought to determine the feasibility of targeting both the
CD47 and CD271 antigens to determine the therapeutic effects
of a pro-phagocytic response, combined with the elimination
of CD271+ tumor cells, on melanoma metastasis.
Here we find that CD47 is expressed on all clinical melanoma
samples, including first-passage xenografts, and that the fre-
quency of CD47+melanoma cells is significantly higher in tumors
isolated from metastatic sites compared to tumors from primary
sites.Wenext demonstrate that antibodies that block the interac-
tion of CD47 with SIRPa increase phagocytosis of melanoma
cells in vitro. We further establish that the combination of CD47
blocking with the targeting of CD271+ cells using CD271-saporin
antibody greatly reduces metastases of xenotransplanted
clinical samples of human melanoma in vivo. Significantly, we
show that the therapeutic effects of these antibodies are medi-
ated by remodeling the immunemicroenvironment of the primary
tumor andmetastatic sites. As a result of CD47 blockade,macro-
phageswere dramatically increased over undifferentiatedmono-
cytes at primary tumor sites,while at the same time theyharbored
lower frequencies of pro-metastatic CCR2+/VEGFR1+ subsets.
Moreover, myeloid cells infiltrating the tumor in control mice
were found to express higher levels of Mrc1, Fizz1, Mgl1, Ym1,
and Il10—characteristic of immune cells that positively regulate
tumor growth and dissemination. Mice treated with CD47 block-
ing monoclonal antibody (mAb) also exhibited an increase in
differentiated macrophages at pulmonary sites of metastasis. In
contrast, lungs of control mice were dominated by neutrophils,
previously shown to positively regulate the homing of metastatic
cells (Cools-Lartigue et al., 2013; Fridlender and Albelda, 2012).
Taken together, these results provide direct evidence that
targeting melanoma immune-evasive properties and CD271+
melanoma cells represents a very effective regimen against
aggressive metastatic disease.
RESULTS
CD47 Expression Is Upregulated in Metastases
Compared to Primary Tumors in Melanoma Patients
CD47 is overexpressed on the cell surface of hematopoietic ma-
lignancies, protecting them from phagocytosis by macrophages
as the disease is spread through the blood and lymphatic sys-
tems (Jaiswal et al., 2009). In this study, we sought to first
examine whether CD47 plays a similar role in melanoma tumors.
Multiple surgical samples representing primary tumors and me-
tastaseswere collected frommelanoma patients immediately af-
ter surgery and processed into viable single-cell suspensions as
previously described (Boiko, 2013; Boiko et al., 2010). Patient
cells were then incubated with fluorescently labeled anti-CD47
mAb (along with mAbs to gate out non-tumor cells) and analyzed
for the presence of cell-surface CD47 by fluorescence-activated
cell sorting (FACS). Alternatively, clinical tumor samples thatwere
too small to isolate sufficient numbers of cellswere implanted into
NSG mice, after which first-passage xenografts were used to
generate viable single-cell suspensions for FACS analysis.
From these experiments, we found that CD47+ melanoma cells
comprised 30%–99% of the entire tumor cell population (Fig-
ure 1A, left) among various patients. Importantly, the proportion
of melanoma cells that were CD47+ in metastatic lesions was
significantly higher (mean 87%) than the proportion ofmelanoma
cells that were CD47+ in primary tumors (mean 61%, p < 0.05)
(Figure 1A, right). To further investigatewhetherCD47expression
increases as melanoma progresses from primary to metastatic
form, we analyzed a previously reported cohort of melanoma pa-
tients (Xu et al., 2008) (n = 85) containing clinical information
linked to the gene expression profile for every tumor. This anal-
ysis revealed that CD47 expression is significantly elevated in
metastatic lesions compared to primary tumors (p = 8.4e5)
(Figure 1B, left). We next analyzed cutaneous melanoma cases
(n = 310) collected as part of The Cancer Genome Atlas (TCGA)
project. Based on pathological data, we were able to classify
mostmelanoma lesions into fourmain categories: primary tumor,
regional cutaneous metastasis, regional lymph node metastasis,
and distant metastasis (DM). Comparison of CD47 expression
between these categories revealed a significant increase in
CD47 mRNA between the primary tumor site and both regional
cutaneous (p = 0.043) and lymph node (p = 0.002) metastasis
(Figure 1B, right). At the same time, CD47 expression in a much
smaller group of melanoma samples isolated from DM sites did
not differ significantly from samples isolated from primary sites
(Figure 1B, right). Overall, our examinationof two largemelanoma
patient cohorts (430 total samples), with the exception of DM
samples (n = 38), revealed a significant positive correlation be-
tween overexpression of CD47 and metastatic melanoma.
Treatment of Melanoma Cells with Anti-CD47
Antibodies In Vitro Enables Macrophage-Mediated
Phagocytosis
CD47 expressed on the surface of target cells can interact with
the SIRPa receptor on macrophages, leading to the inhibitionof macrophage-mediated phagocytosis (Chao et al., 2012; Oka-
zawa et al., 2005). To determine whether CD47 present on
metastatic melanoma cells plays a protective role against
macrophages, we analyzed the ability of tumor cells to resist
phagocytosis in the presence and absence of CD47 blocking
antibody. To conduct these experiments, we fluorescently
labeled metastatic melanoma cells (M213) with carboxyfluores-
cein succinimidyl ester (CFSE) dye and co-incubated them
with activated NSG mouse bone marrow-derived macrophages
in the presence of IgG1 isotype control or blocking CD47 mAb
(B6H12). This antibody was previously shown to bind to the
CD47 antigen, thereby inhibiting the interaction between CD47
and SIRPa and enabling phagocytosis (Jaiswal et al., 2009). Us-
ing in vitro assays measuring the macrophage phagocytic index,
we revealed that blocking CD47 antibody promotes efficient
phagocytosis of melanoma cells by macrophages compared to
matched IgG controls (Figure 2A). To demonstrate the effects
of CD47 blockade on macrophage-induced phagocytosis
of melanoma in a broader context, we examined additional
patient-derived cells representing metastatic variants of the
disease (M727 and M1626). In these experiments, we used
GFP-expressing lentiviral vector and FACS to derive homoge-
neously labeled GFP populations from each tumor sample
(M213, M727, and M1626). GFP-labeled melanoma cells were
then co-incubated with activated macrophages in the presence
of a humanized CD47 blocking mAb (hCD47b) (Hu5F9-G4;
Lonza) or control IgG as described above. Next, we labeled
macrophages with macrophage-specific fluorescently conju-
gated antibody (F4/80) and used FACS to measure phagocytic
efficiency by determining the frequency of double-positive
(GFP+, F4/80+) cells. Our results convincingly demonstrate that
CD47 blocking antibody induced efficient phagocytosis of
metastatic melanoma (Figures 2B–2D). These findings also
demonstrated interspecies cross-reactivity between mouse
macrophages and human melanoma cells and paved the way
for in vivo studies using amelanoma xenograft model. It is impor-
tant to note that the CD47 blocking antibody did not cause tumor
cell death prior to phagocytosis.
Generation of Patient-Derived Xenograft Metastatic
Models of Melanoma
Upon demonstrating that CD47 was abundant on human mela-
noma tumors and that blocking CD47 was sufficient to induce
phagocytosis in vitro, we sought to examine the therapeutic po-
tential of anti-CD47 antibodies in vivo using a mouse xenograft
model of metastatic melanoma. Although many melanoma cell
lines and their metastatic derivatives have been established
in vitro and shown to have highly invasive and aggressive pheno-
types, the extent to which these phenotypes reflect original dis-
ease characteristics as opposed to changes acquired during the
course of adaptation to tissue-culture conditions is unclear.
Thus, we decided to establish mouse xenograft models of met-
astatic melanoma that recapitulate the progression of human
disease using freshly obtained surgical samples. Through this
process, we identified a human melanoma sample (M213) that,
upon intradermal injection into mouse skin, forms primary tu-
mors at injection sites that later metastasize to the lymph nodes
and visceral organs, typically the lungs and liver (Figure S1A).Cell Reports 16, 1701–1716, August 9, 2016 1703
Figure 1. CD47 Is Upregulated in Human Melanoma Metastases
(A) Frequency of CD47+melanoma cells in patient tumors excised frommetastatic locations compared to primary lesions as determined by FACS.Gating strategy
for CD47+ melanoma cells (gray histograms) was set up in accordance with the isotype controls (red histograms) conjugated to the same fluorochrome as CD47
mAb. Horizontal bars illustrate mean values for each group.
(B) Relative CD47 mRNA expression was analyzed for previously reported cohorts of melanoma patients GSE8401 (n = 85) and TCGA_SKCM (n = 310) who were
subdivided into primary and metastasis categories based on clinical information. The TCGA_SKCM cohort contains primary tumor (PT), regional cutaneous
metastasis (RCM), regional lymph node metastasis (RLM), and distant metastasis (DM) subgroups. ns, not significant.Consistent with our earlier findings in human patient samples,
cell-surface CD47 levels increase significantly for melanoma
cells that form pulmonary metastasis in mice (Figure S1B).1704 Cell Reports 16, 1701–1716, August 9, 2016Next, we established a second, independent metastatic xeno-
graft model from patient M727. Intradermal injection of M727
into mouse skin resulted in the formation of primary tumors
Figure 2. Blockade of CD47 on the Cell Surface of Melanoma Cells by mCD47b and hCD47b mAbs Induces Their Effective Phagocytosis by
Activated Macrophages
(A) Phagocytic index of M213 cells that were labeled with CFSE dye and incubated with NSG mouse bone marrow-derived macrophages in the presence of
mCD47b (B6H12; Bio X Cell) blocking mAb or matching IgG control. Representative images of co-cultured melanoma cells and NSG mouse bone marrow-
derived macrophages following antibody treatment are shown. Black arrows indicate melanoma cells that had not been phagocytosed by macrophages; red
arrows point to phagocytosed tumor cells.
(B–D) Phagocytosis of GFP-labeled M213, M727, and M1626 patient-derived melanoma cells that were co-incubated with bone marrow-derived NSG mac-
rophages in the presence of hCD47b (Hu5F9-G4; Lonza) blocking mAb or IgG control.
Data are shown as means with SDs.
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that later metastasize to the lungs and kidneys, without affecting
lymph node compartments. Establishing these models enabled
us to assess the effects of antibody treatment on different types
of melanoma metastasis and stages of disease progression.
Blocking CD47 and Cytotoxic CD271 Antibodies Inhibit
Melanoma Metastasis In Vivo
We previously demonstrated that in human melanomas, cells
that have increased tumor-initiating capacity and also give
rise to metastatic subpopulations express CD271 (Boiko et al.,
2010). Because the process of metastasis requires evasion of
the innate immune system, we investigated how direct targeting
of CD271+ melanoma cells and blockade of CD47 antigen would
affect tumor progression, using the metastatic xenograft models
described above. In these experiments, we utilized hCD47bmAb
(Willingham et al., 2012) and a CD271-saporin mAb (CD271S),
which is capable of selectively killing CD271+ cells by delivering
an inhibitor of ribosomal assembly (saporin) to cells expressing
theCD271 receptor on their surface (Fine et al., 1997) (Figure S2).
The general outline of the experiment is shown in Figure 3A:
10,000 M213 cells were introduced intradermally into NSG
mice via unilateral injection of the single-cell suspension inMatri-
gel into the right flank of the back of the animal. Melanoma cells
were given 4 weeks to grow and form tumors, a time frame that
we previously determined to correspond to the onset of tumor
metastasis. Animals were randomly divided into four antibody
treatment groups (each group n = 6 for experiment 1 and n = 4
for replicate experiment 2): IgG control, hCD47b, CD271S, and
a combination of hCD47b and CD271S. Antibody administration
was performed once every 2 days for 32 days, after which all
animals were sacrificed and examined for primary and metasta-
tic melanoma growth. Upon gross pathological examination,
metastasis was detected in multiple organs, including lymph
nodes, lungs, and liver, in control (IgG)-treated mice. Strikingly,
administration of hCD47b, CD271S, or both hCD47b and
CD271S significantly reduced the presence of metastatic lesions
in all the organs mentioned above and, in some animals, gener-
ated a complete response, resulting in the absence of detectable
metastatic growth in lymph nodes and visceral sites (Figures 3C–
3F). At the same time, mAb therapy had only a partial effect on
established primary tumors, decreasing tumor volume by a
mean of 16.5% (p = 0.18) after CD271S administration, 46%Figure 3. Administration of Antibodies Blocking Tumor CD47 and Targ
Distant Melanoma Metastases
Plotted data points for tumor volume andmetastatic lesion/organ count represent
2 n = 4 for each treatment group).
(A) General outline of the experiment. Antibodies were injected once every 2 days a
hCD47b + CD271S, 100 mg + 1 mg, respectively.
(B) Primary tumor volumes at the end of each indicated treatment.
(C) Analysis of LNs from all treatment groups reveals dramatic reduction in metast
to control IgG.
(D) Representative experiment (experiment 1 n = 6) analysis of metastatic LN locat
mAbs. N, none.
(E and F) Pathological examination of lungs (E) and livers (F) from all treatment grou
the indicated mAb administration. Representative areas of H&E-stained tissues c
lines.
Horizontal bars illustrate mean values for each group. p values were calculated u
****p < 0.0001).(p = 0.001) after hCD47b administration, and 57% (p < 0.001) af-
ter combined hCD47b and CD271S administration (Figure 3B).
Notably, when the cellular composition of treated tumors was
analyzed, we discovered that administration of hCD47b alone
or in combination with CD271S not only reduced tumor size
but also significantly decreased the proportion of human mela-
noma cells within tumors (Figure S3), which also contained cells
of inflammatory, stromal, vascular, and blood lineages, among
others.
During melanoma pathogenesis, the onset of metastatic dis-
ease is often associated with lymph node (LN) metastasis,
most affecting LNs closest in proximity to the primary tumor
site. Despite the fact that the primary tumors grew on the upper
right side of the back of all treated mice, in the control (IgG)-
treated group large metastatic lymph nodes were detected on
both lateral sides inmost of the animals, many of which had large
metastatic growth at the axillary and inguinal LN locations (Fig-
ure 3D) in the same animal. This indicated rapid spread of
metastasis, characteristic of melanoma pathogenesis. In sharp
contrast, mice treated with CD271S displayed significant reduc-
tion in the size and number of metastatic LNs (Figure 3C), which
appeared primarily on the right side of the body at the axillary
location (Figure 3D). More pronounced results were observed
in hCD47b-treated mice: metastatic LNs were absent on
average in 50% (3/6 and 2/4) of examined animals (Figure 3C).
Combined hCD47b and CD271S treatment yielded the most
striking effect: on average, 70% of animals (4/6 and 3/4) had
no detectable LN metastases. Moreover, in the animals that
were affected, LN metastasis was restricted to a single small
metastatic LN on the right axillary site (Figure 3D). Very impor-
tantly, examination of visceral organs revealed that lung metas-
tases were significantly reduced after CD271S mAb administra-
tion (Figure 3E), whereas administration of hCD47b reduced
them even further and a combination of both mAb treatments
in the same animals virtually eliminated metastatic disease
from their lungs (Figure 3E). In drastic contrast, 90% of control,
IgG-treated mice developed numerous (>150) large pulmonary
metastases. As melanoma progresses to more advanced
stages, metastasis often affects multiple organ systems, repre-
senting amajor challenge for existing therapies, which eventually
fail due to widespread disease. In our xenograft model of human
metastasis, M213 cells also metastasize to the liver, in additioneting CD271+ Melanoma Cells Results in Elimination of Regional and
a combination of two replicate experiments (experiment 1 n = 6 and experiment
t the following doses: IgG control, 100 mg; hCD47b, 100 mg; CD271S, 1 mg; and
atic LN burden and size after treatment with the indicated mAbs in comparison
ion and their distribution throughout the body of mice treated with the indicated
ps of mice reveals significant reduction inmetastatic lesions in each organ after
ontaining metastatic foci are shown at 43 magnification and traced by brown
sing unpaired parametric Student’s t test (*p < 0.05, **p < 0.005, ***p < 0.0005,
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to the LNs and lungs. Examination of control, IgG-treated mice
revealed liver metastases on average in 80% of animals (5/6
and 3/4), ranging from 3 to 13 lesions (Figure 3F). Treatment of
mice with CD271S significantly reduced liver metastasis: on
average, only 30% of animals (2/6 and 1/4) had detectable met-
astatic lesions. Even more strikingly, administration of hCD47b
alone or in combination with CD271S completely prevented liver
metastasis in 100% of animals, per detailed pathological exam-
ination (Figure 3F). Overall, we observed progressive diminish-
ment of metastatic burden (particularly that of LNs) that was
correlated with the reduction of primary tumor volumes. Further
experiments will be required to determine the extent to which
tumor volume and dissemination of metastatic cells are corre-
lated, and whether any paracrine factors secreted by primary tu-
mor cells support the homing and survival of their metastatic
counterparts.
To evaluate the effect of the treatment antibodies on the early
onset of metastases, we transplanted 100,000 M213 cells intra-
dermally into NSG mice as described above and began treating
them 14 days after cell implantation (Figure S4A). After 10 days
of treatment, all mice were sacrificed and their tissues were
examined for metastatic lesions. As in the experiments
described above, we observed greatly reduced lung metastases
and the complete absence of metastatic LNs in both mouse
CD47 blocking mAb (mCD47b)- and CD271S-treated animals
(Figure S4B). A decrease in metastases was accompanied by
partial reduction of tumor volume, which, although significant
in the case of mCD47b-treated tumors (34%, p = 0.012), was
not significant for CD271S-treated tumors (13.5%, p = 0.20) (Fig-
ure S4C), indicating that primary tumor size reduction is not the
sole mechanism through which mAb action suppresses the
development of metastases.
In order to validate our findings in an independent metastatic
melanoma model, we utilized M727 patient-derived cells. As
indicated above, upon intradermal xenotransplantation into
NSG mice, these cells form skin melanomas that later metasta-
size to the lungs and kidneys, without affecting the animals’
LNs. This allowed us to test the effectiveness of blocking CD47
and targeting CD271+ cells in a melanoma model characterized
by a different mechanism of metastasis (metastasis of primary
melanoma cells through the blood vasculature but not the
lymphatic system). The general outline of the experiment is
shown in Figure 4A; melanoma (M727)-bearing mice were
treated with the indicated antibodies for 39 days, after which
all animals were sacrificed and examined for metastatic mela-
noma growth. Upon pathological examination, we detected
that lungs from control-treatedmice contained grossly deformed
tissues that consisted of large metastatic lesions fused together,
essentially replacing epithelial lung structures with tumor cells, in
100% of cases (Figure 4B). We calculated themetastatic area in-
dex (MAI) in these animals by taking the ratio of tumor area to to-
tal lung area in the examined cross-section. Treatment of mice
with CD271S resulted in, on average, a 2-fold decrease in MAI,
with the worst-affected animal having a 0.23 MAI (23% of lung
area colonized by metastatic tissue) compared to 0.43 MAI for
the worst-affected control animal (43% of lung area colonized
by melanoma). Administration of hCD47b alone or in combina-
tion with CD271S resulted in nearly complete elimination of1708 Cell Reports 16, 1701–1716, August 9, 2016lung metastasis in 100% of treated animals, with only a few mi-
cro-metastases (mets) existing throughout the entire lung area
per histological examination (Figure 4B). Furthermore, analysis
of kidneys revealed large metastatic lesions in 100% of control
animals, ranging from 3 to 18 macro-mets per animal. Targeting
CD271+ melanoma cells with CD271S significantly reduced the
number of kidney mets, ranging from 0 to 3 micro-mets per an-
imal (Figure 4C). Importantly, administration of hCD47b alone or
in combination with CD271S achieved the best response, almost
completely eliminating kidney metastasis, per histopathological
analysis (Figure 4C).
In summary, these results provide strong evidence that mela-
noma metastasis can be effectively treated and suppressed by
blocking CD47 antigen with CD47b mAb on tumor cells, and
that this therapeutic effect is augmented by specifically targeting
CD271+ melanoma cells with CD271S mAb.
CD47 Treatment Increases Macrophage Density and
Changes the Balance of Pro-Metastatic and Anti-Tumor
Myeloid Cells
Tumor immune microenvironment has been shown to play a
pivotal role in carcinogenesis by either inhibiting or promoting
tumor growth, depending on its cellular composition (Qian and
Pollard, 2010). To investigate how the immune cell composition
of a tumor changes following mAb treatment in melanoma-
bearing NSG mice, we resected primary tumors at the end of
each treatment and performed rigorous immunohistochemical
(IHC) and FACS analysis of myeloid cell populations. IHC
staining of tumors from each treatment group using the macro-
phage-specific mAb F4/80 indicated that CD47 blockade in-
duces a massive increase of differentiated macrophages within
the tumor (Figure 5A). We next performed flow cytometric anal-
ysis of treated tumors following their resection and isolation
into single-cell suspensions to determine the types of immune
cells infiltrating the tumor. Remarkably, we discovered that in
control (IgG)- or CD271S-treated tumors, up to 85% of the
myeloid lineage comprised inflammatory monocytes (Lin,
CD45+, Ly6Chi, CCR2+, CD11blo, CD11c, F4/80) and only
10% comprised differentiated macrophages (Lin, CD45+,
CD11b+, F4/80+, Ly6Clo-hi, Ly6G). In sharp contrast, tumors
treated with hCD47b, whether alone or in combination with
CD271S, contained significantly fewer inflammatory monocytes
and many more differentiated macrophages (45% and 42%,
respectively) (Figure 5B).
Recent studies of epithelial malignancies suggest that macro-
phages, characterized by the expression of VEGFR1 and CCR2,
aide tumor cells in migrating from their primary site and seeding
metastatic growth at distant organs (Qian et al., 2011; Ren et al.,
2012). We therefore analyzed the frequency of these pro-
metastatic macrophages in tumors from each treatment group.
Flow cytometric analysis of treated tumors revealed that com-
bined hCD47b and CD271S mAb administration resulted in an
almost 2-fold reduction in the frequency of pro-metastatic mac-
rophages (Lin, CD11b+, F4/80+, Ly6Clo-hi, Ly6G, VEGFR1+/
CCR2+) compared to control (IgG)-treated mice: 6% and
11.5%, respectively (Figure 6A). Recent evidence indicates
that VEGFR1+/CCR2+ macrophages not only influence the
tumorigenic properties of primary tumor cells but are also
Figure 4. Antibody Therapy of Blocking
CD47 and Targeting CD271+ Melanoma
Cells Significantly Reduces Lung and Kid-
ney Metastases
(A) General outline of the experiment. Mice bearing
M727 melanomas were randomized into four treat-
mentgroups (n=4,exceptCD271Sn=3)andtreated
with the indicated mAbs for 39 days at the following
doses: IgG control, 100 mg; hCD47b, 100 mg;
CD271S, 1 mg; and hCD47b + CD271S, 100 mg +
1mg, respectively. At theendof the treatment, organs
fromall treatedmicewere removedandexamined for
the presence of metastatic melanoma foci.
(B and C) Pathological analysis of lungs (B) and
kidneys (C) from each treatment group reveals
significant reduction of metastases in these or-
gans. Representative areas of each H&E-stained
tissue are shown at 203 magnification, and met-
astatic lesions are traced by brown dotted line or
indicated by black arrows. Horizontal bars illus-
trate mean values for each group.
*p < 0.05, **p < 0.005, ***p < 0.0005.recruited to pulmonary sites and positively regulate extravasa-
tion and initiation of metastatic growth (Ren et al., 2012). In our
experiments, these macrophages were present in lungs fromCell Reall treatment groups; however, we found
that combined hCD47b and CD271S
treatment (resulting in themost significant
decrease of pulmonary metastatic bur-
den) induced a 7-fold reduction in the fre-
quency of pro-metastatic macrophages
compared to control treated group
(0.27% and 2%, respectively) (Figure 6B).
We next characterized the expression
of specific genes commonly upregulated
in myeloid cells found at tumor sites and
associated with disease progression
(Franklin et al., 2014). Using real-time
PCR, we found that tumors treated with
hCD47b alone or in combination with
CD271S contained myeloid cells that
expressed significantly lower levels of
Mrc1, Ym1, Mgl1, Fizz1, and Il10 (Fig-
ure S5). Unexpectedly, we found no differ-
ence in Arg1 and Il12 expression and
lower levels of Nos2 in the same cells as
compared to control-treated mice. Inter-
estingly, a previous report indicated that
macrophages whose SIRPa had been
activated byCD47antigenbinding display
increased NO production (Alblas et al.,
2005). Our results directly support this
notion demonstrating that blockade of
CD47 with mAbs decreases expression
of Nos2 mRNA, which encodes the key
enzyme inNOsynthesis, iNOS (Figure S5).
Because CD47 is expressed in virtually
all hematopoietic cell lineages, we testedhCD47b mAb binding to mouse myeloid cell subsets to rule out
the possibility that the aforementioned changes in the immune
cell profiles of treated mice are caused by antibody binding.ports 16, 1701–1716, August 9, 2016 1709
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We co-incubated freshly isolated mouse macrophages and neu-
trophils, as well as human melanoma (M727) cells, with hCD47b
mAb, which was then detected by fluorescently conjugated sec-
ondary antibodies (IgG4-FITC [fluorescein isothiocyanate]). Our
results validate that hCD47 mAb is specific to human CD47
only and lacks specific binding activity against the mouse cell
populations tested (Figure S6).
Therapeutic Antibody Treatment Reduces Neutrophil
Infiltration at Metastatic Sites
Similar to pro-metastatic macrophages, neutrophils also play a
significant role in the colonization of visceral organs during
metastasis when recruited to these sites. There are multiple
mechanisms by which neutrophils act to promote the homing
of circulating metastatic cells (CMCs), including contact-depen-
dent tethering of CMCs to end-organ endothelium, formation of
neutrophil extracellular traps (NETs), and secretion of soluble
factors that create a favorable milieu for arriving metastatic tu-
mor cells (Cools-Lartigue et al., 2013; Fridlender and Albelda,
2012). Mounting evidence points to a direct correlation between
poor patient prognosis and high frequencies of neutrophils at
metastatic sites (Sarraf et al., 2009; Walsh et al., 2005). In our ex-
periments described above, we observed significant changes in
some of the myeloid cell lineages that infiltrate tumors during
mAb treatments (Figure 5). To more fully understand the thera-
peutic effects of antibody treatment on melanoma metastasis,
we investigated the visceral organs of experimental mice for
the presence of neutrophils and differentiated macrophages.
Very importantly, we discovered that at pulmonary sites of
melanoma metastasis in control (IgG)-treated mice, up to 75%
of the myeloid cell lineage comprised differentiated neutro-
phils/granulocytes (Lin, CD11b+, F4/80 Ly6Clo, Ly6G+) (Fig-
ure 7A; Figure S7), whereas only 8% comprised differentiated
macrophages. In sharp contrast, when mice were treated with
hCD47b alone or in combination with CD271S, the proportion
of neutrophils/granulocytes decreased to 30%, whereas that of
differentiated macrophages increased to 50% (Figure 7). These
drastic changes in the myeloid cell microenvironment provide
an additional mechanism by which to explain the potent thera-
peutic effect of hCD47b and combined hCD47b and CD271S
mAb treatments against visceral metastasis.
DISCUSSION
In this study, we used surgical melanoma samples and gene
expression datasets to confirm CD47 as a marker of metastatic
melanoma development and demonstrate its role in disease pro-
gression. Blocking theCD47antigenwith hCD47bmAb,which ac-
tivatesmacrophage-inducedphagocytosis, considerably reduced
melanoma metastasis in a mouse xenograft model of human dis-Figure 5. Blockade of CD47 Antigen on the Surface of Tumor Cells Ch
Site
(A) Immune fluorescence tumor analysis of infiltrated macrophages using mF4/8
(B) The frequency of myeloid cell lineages at the primary tumor site in each trea
staining it with a panel of cell-surface markers specific for the following populatio
CCR2+), macrophages (LinCD11b+ F4/80+ Ly6Clo-hi Ly6G), and neutrophils (Lin
instrument.ease. When this treatment is combined with mAbs targeting
CD271+ melanoma cells, which were previously determined to
have tumor- and metastasis-initiating properties (Boiko et al.,
2010; Civenni et al., 2011; Redmer et al., 2014), the therapeutic ef-
fectofCD47blockade isenhancedeven further.Wealsoshowthat
theanti-metastaticpropertiesofCD47blockadeon tumor cells not
only induce their phagocytosis in vitro and reduce their metastasis
in vivo but also result in critical changes in the tumor site immune
microenvironment by increasing the density of differentiated
macrophages and decreasing the presence of inflammatory
monocytes, pro-metastaticmacrophages, and neutrophils (at pul-
monarymetastases), all threeofwhichare associatedwithdisease
progression. Because hCD47bmAb treatment also results in par-
tial reduction of primary tumor volume, which may affect its ability
to metastasize, further research is required to delineate the anti-
metastatic properties of hCD47b mAb treatment, independent of
its effects on primary tumor growth. In a model of metastatic leio-
myosarcoma, which is also susceptible to CD47 blockade,
surgical excision of primary tumors during the first week of
treatment still resulted in the significant reduction of metastases
at visceral sites (Edris et al., 2012). Combined with the data
presented in this study, it indicates the strong potential of CD47
treatment as a neoadjuvant therapy for melanoma patients whose
primary cutaneous tumors had been previously removed.
Integrin-associated protein CD47 plays a ‘‘self-signal’’ role by
binding to the SIRPa receptor on macrophages and preventing
their phagocytic function (Majeti et al., 2009; Okazawa et al.,
2005; Vernon-Wilson et al., 2000). Overexpression of CD47 on
the cell surface of normal hematopoietic stem cells (HSCs) has
been shown to play a protective role when these cells travel
through the bloodstream during mobilization from the bone
marrow to various tissue sites (Jaiswal et al., 2009). Metastasis,
the primary cause of death for many cancers, including mela-
noma, occurs by active migration mechanisms that involve tu-
mor cell intravasation, survival in the bloodstream, extravasa-
tion, and the ability to proliferate at distant sites. Macrophages,
a major part of innate immune surveillance, react to the presence
of metastasizing cells at primary or visceral locations by binding
to and phagocytosing these cells to prevent the spread of dis-
ease. Our analysis of CD47 expression in primary andmetastatic
tumor sites from melanoma patient databases and our in vivo
CD47 blocking experiments provide evidence that melanoma
cells that acquire a metastatic phenotype and colonize other or-
gans employ the same anti-phagocytic protection mechanism
as do mobilized HSCs.
Inhibition of CD47 using monoclonal antibodies was recently
demonstrated to effectively eliminate hematologic and epithelial
malignancies (Chao et al., 2010; Majeti et al., 2009; Willingham
et al., 2012). However, for tumors of neural crest origin—in
particular human melanoma—the relevance of this molecule isanges the Repertoire of Myeloid Cell Lineages at the Primary Tumor
0-A647 mAb. Red color indicates positive F/480 staining.
tment group was determined by isolating a tumor single-cell suspension and
ns: inflammatory monocytes (Lin, CD11blo, CD11c, F4/80, Ly6Chi, Ly6G,
, CD11b+, F4/80 Ly6Clo Ly6G+) that were then analyzed using a BDFACSAria
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Figure 6. CD47 Blockade on Tumor Cells Decreases the Frequency
of Pro-Metastatic Macrophages at Primary and Pulmonary Sites
M213 tumor-bearing mice were treated with the indicatedmAbs and, at the end
of the treatment, tumors and lungs were surgically removed and digested into a
single-cell suspension. Cells were stained with a combination of cell-surface
markers allowing quantitation of variousmacrophage populations. Frequency of
pro-metastaticmacrophages in the tumor (A) and lung (B)was determined as the
percentageof LinCD11b+F4/80+ Ly6Clo-hi Ly6G, CCR2+/VEGFR1+cells in the
total macrophage population. Data are shown asmeanswith SDs. p valueswere
derived using unpaired parametric Student’s t test (*p < 0.05, **p < 0.005).only beginning to emerge. In a murine model of melanoma,
B16F10, small interfering RNA (siRNA) targeting CD47 was
shown to be effective against mouse tumors, suggesting that
mRNA levels of CD47 are important for tumor homeostasis
(Wang et al., 2013). Nonetheless, a significant gap exists be-
tween the B16F10 mouse melanoma model and the safe thera-1712 Cell Reports 16, 1701–1716, August 9, 2016peutic delivery of siRNA into human patients. In the current
study, we utilized a therapeutically developed and humanized
mAb blocking CD47 and metastatic melanoma cells derived
from clinical human samples to demonstrate that blockade of
CD47 antigen by administering CD47b mAb considerably re-
duces metastasis in vivo. Significantly, these results confirmed
our hypothesis that the CD47 antigen on metastatic melanoma
cells plays a protective role against macrophage attack.
In most adult tissues, resident macrophages are derived from
bone marrow monocytes. Classically differentiated macro-
phages are capable of eliciting anti-tumor responses, resulting
in cell phagocytosis and antigen presentation. Accumulating ev-
idence indicates that myeloid cell lineages, although helping the
immune system to recognize and eliminate cancer cells, can also
be subverted by tumors to play a supportive role for tumor pro-
gression andmetastasis (Biswas andMantovani, 2010;Murdoch
et al., 2008). Both alternatively activated macrophages (CCR2+/
VEGFR1+) and neutrophils have been shown to promote meta-
static cell growth and seeding at distant organs (Cools-Lartigue
et al., 2013; Qian et al., 2011; Ren et al., 2012). Alternativemacro-
phage differentiation occurs in response to multiple external and
internal factors and results in cells that aid tumor growth via cyto-
kine secretion, stimulation of blood vessel growth, andmatrix re-
modeling. Neutrophils (also derived frommyeloid precursors) aid
colonization of visceral organs by several independent mecha-
nisms that involve formation of NETs and secretion of soluble
factors that promote the adhesion of circulating tumor cells to
an organ’s endothelium (Cools-Lartigue et al., 2013; Fridlender
and Albelda, 2012). Thus, the balance between different myeloid
cell populations can be a critical determinant of eventual disease
outcome and serve as a therapeutic target. In our current study,
we demonstrate that blocking the CD47 antigen on the surface of
tumor cells initiates a chain of events that changes the tumor im-
munemicroenvironment by significantly increasing the presence
of anti-tumor macrophages and decreasing the presence of
undifferentiated monocytes and pro-metastatic macrophages
at primary tumor sites. Similar changes occur at the pulmonary
sites of metastasis that harbor increased concentrations of
anti-tumor macrophages and have a greatly decreased density
of neutrophils. Because the hCD47b mAb is human specific
and does not display binding activity against the murine CD47
antigen, observed changes in the type and number of myelomo-
nocytic cells in treated melanomas at primary and metastatic
locations must result from the biological effects of this antibody
on the human tumor cells, and not the antibody-mediated killing
of neutrophils and/or macrophages. Further studies will be
required to elucidate the exact mechanisms by which CD47-
induced phagocytosis of tumor cells affects macrophage
polarization and monocytic lineage differentiation at the sites of
actively proliferating disease.
During the last two decades, researchers have made
numerous attempts to translate knowledge of immune system
regulation into potent immune therapies in melanoma. These
were mostly focused on potentiation of T cell responses
and include administration of high-dose interleukin 2 and autol-
ogous cell transplantations that utilize patient-derived tumor-
infiltrating lymphocytes or genetically engineered T cells against
known melanoma tumor antigens such as TYR, MART-1, or
Figure 7. CD47 Blockade on Tumor Cells Reduces Neutrophil and Increases Differentiated Macrophage Densities at Pulmonary Sites of
Metastasis
(A) M213 tumor-bearing mice were treated with the indicated mAbs, after which their lungs were surgically removed and digested into a single-cell suspension.
Cells were stained with the combination of cell-surface markers specific for the following populations: inflammatory monocytes (Lin, CD11blo, CD11c, F4/80,
(legend continued on next page)
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NY-ESO-1 (Cormier et al., 1997; Dudley et al., 2001; Morgan
et al., 2006; O’Neil et al., 1993). More recent approaches also
included application of monoclonal antibodies that target inhib-
itory immune checkpoints (CTLA-4) or anti-apoptotic pathways
(PD-1/PDL1) to increase the cytotoxic anti-tumor response (Call-
ahan et al., 2015; Hodi et al., 2010; Ribas et al., 2016). Recent
clinical trial data show that ipilimumab and nivolumab are
capable of inducing an objective response (OR) in 10%–43%
of advanced melanoma patients, with the most effective
regimen, based on concurrent administration of both antibodies,
resulting in an OR rate of 61% (Postow et al., 2015; Robert et al.,
2015). Although studies to determine disease-free survival rates
in these patients are still ongoing, the latest clinically available
data among ipilimumab-treated groups indicate that median
overall survival was 9.5 months (95% confidence interval [CI],
9.0–10.0 months), with a 3-year survival rate of only 21% (95%
CI, 20%–22%) (Schadendorf et al., 2015). This indicates that a
significant proportion of patients still succumbs to the disease,
most likely as a result of tumor adaptation that allows it to
bypass recognition by activated T cells. Therefore, investigations
continue to find regimens and cellular therapies that can be used
in combination with T cell-activating approaches and thus signif-
icantly diminish the chances that resistant tumor clones emerge
quickly in the patient. In this report, we provide biological evi-
dence that blockade of CD47 activates strong anti-tumor pro-
phagocytic response in vitro. A similar mechanism involving
macrophage-induced phagocytosis of cancer cells may be
responsible for the observed anti-metastatic effects of CD47b
antibody in vivo. Thus, activation of innate immunity based on
macrophage-induced phagocytosis can be harnessed as an
effective therapeutic strategy against metastatic melanoma.
Our findings also indicate that a treatment regimen aimed
against multiple mechanisms of melanoma progression
(blockade of CD47 antigen and targeting of the CD271+ mela-
noma-initiating cell subset) produces the most effective thera-
peutic response.
As clinical trials uncover the therapeutic effectiveness of anti-
bodies targeting T cell checkpoint inhibitors, the data presented
here on the antibodies that induce the anti-tumor macrophage
response should lead to studies testing the synergy of activating
both adaptive (the T cell response) and innate (macrophage-
mediated phagocytosis) components of the immune system in
advanced melanoma patients. Combining this strategy with the
targeting of melanoma-initiating (CD271+) cells may represent
a synergistic therapy that more effectively activates the overall
immune response against melanoma.
EXPERIMENTAL PROCEDURES
Human Samples
Human melanoma samples were obtained from consented patients at Stan-
ford Hospital, per protocols approved by the Institutional Review Board of
the Stanford University School of Medicine.Ly6Chi, Ly6G, CCR2+), macrophages (LinCD11b+ F4/80+ Ly6Clo-hi Ly6G), and
a BD FACSAria instrument.
(B) Immune fluorescence lung tissue analysis of infiltratedmacrophages. At the en
anti-F4/80-A647 antibody, and imaged at 203 resolution. Red color indicates po
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For CD47 expression, surgical melanoma samples excised from primary and
metastatic sites were dissociated into single-cell suspensions as previously
described (Boiko, 2013; Boiko et al., 2010). Cell suspensions were stained
with hCD47-phycoerythrin (PE) Ab and lineage (Lin) Abs: hCD45-Pacific blue
(PB), hCD31-PB, and hCD235a-PB. For analysis of tumor- and lung-infiltrating
cell populations, these tissues were digested into single-cell suspensions and
stained with the following mAbs conjugated to the indicated fluorochromes:
mCD45-PB, mCD11b-PeCy7, mCD11c-allophycocyanin (APC), mF4/80-APC,
mLy6C-FITC,mLy6G-PE,mVEGFR1-APC, andmCCR2-A700. Flow cytometric
analysis of stained cells was performed using a BD FACSAria instrument.
Analysis of CD47 mRNA Expression
Gene expression and clinical data were analyzed for previously described co-
horts of melanoma patients: GSE8401 (n = 83) and TCGA_SKCM (n = 310). For
GSE8401, Affymetrix probeset summaries were derived after normalizing the
dataset with RMA (http://rmaexpress.bmbolstad.com/). Mean CD47 mRNA
expression was computed based on probeset ID 211075_s_at using R soft-
ware (https://www.r-project.org/). For melanoma TCGA, RNA-sequencing
reads were processed with R_subread version 1.14.2 of the R package and
summarized gene values were normalized to fragments per kilobase of tran-
script permillionmapped reads (FPKM). Subsequently, CD47 gene expression
was evaluated using ‘‘R Stats’’ R software version 3.2 in 310 subjects whose
melanoma lesions were classified as primary tumor, regional cutaneous
metastasis, regional lymph node metastasis, and distant metastasis.
Antibody Treatment of Xenograft Tumors
Mice bearing human melanoma tumors (M213 or M727) were randomized into
four treatment groups: IgG (BD Pharmingen) control mAb, blocking anti-
hCD47b (Hu5F9-G4; Lonza) monoclonal antibody, anti-CD271S (ME20.4-Sap;
Advanced Targeting Systems) cytotoxic antibody, and combined blocking
anti-hCD47b and anti-CD271S antibodies. M213, n = 6 for experiment 1 and
n = 4 for replicate experiment 2 in each treatment group; M727, n = 4 in
each treatment group, except CD271S n = 3. IgG control (100 mg) and CD47
antibodies (100 mg) were injected intraperitoneally (100 ml) once every
2 days. CD271S (1 mg) was injected directly into the center mass of the tumor
(50 ml) once every 2 days. Antibody injections began 27 days (M213-injected
mice) or 87 days (M727-injected mice) after initial tumor cell engraftment,
and lasted for 32 and 39 days, respectively.
Quantitative RT-PCR
Total RNA was extracted using TRIzol reagent, and the mRNA was reverse
transcribed into cDNAs using Verso cDNA synthesis kits (Life Technologies)
followed by real-time PCR using LightCycler FastStart DNA Master SYBR
Green I and a LightCycler 780 II (Roche) instrument. Mouse gene-specific
primer sets (summarized in the table in Supplemental Experimental Proce-
dures) were used to detect each mRNA. Expression values were normalized
against B2m using the 2DDCT method (Livak and Schmittgen, 2001). Data
are shown as means with SDs.
Immunohistochemistry
To determine the levels of macrophage infiltration, fluorescence immunohisto-
chemistry was performed on fresh-frozen, OCT-embedded tumor and lung
tissue. Tissues were sectioned at 10 mm and stained with anti-F4/80 antibody.
Slides were scanned and imaged using a fluorescence Nikon Ti-E inverted
microscope.
Statistical Analysis
All data are presented as means ± SDs. Statistical analysis and graph
preparation were performed in Prism 6 (GraphPad Software). p values wereneutrophils (Lin, CD11b+, F4/80 Ly6Clo Ly6G+) that were then analyzed using
d of each treatment, lungs were removed, cryosectioned at 10 mm, stained with
sitive F/480 staining.
calculated using unpaired parametric Student’s t test, assuming equal vari-
ances. Statistically significant difference is marked as *p < 0.05, **p < 0.005,
***p < 0.0001.
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